Identification of a lead hypoxia-activated irreversible pan-HER inhibitor SN32807 (PR509) by pharmacokinetic and anti-tumor efficacy screening in an erlotinib-resistant xenograft model

ResearchSpace/Manakin Repository

Full text options

Find Full text

This item appears in the following Collection(s)

Share

Search ResearchSpace


Advanced Search

Browse